Investment Pitches

Pitch Summary:
Halozyme Therapeutics, Inc. is a leading drug delivery platform company built around its proprietary and commercially validated ENHANZE® technology. This innovative enzyme enables the subcutaneous delivery of biologics and fluids, transforming hours-long intravenous infusions into quick injections delivered in minutes. The technology reduces treatment burden for patients and alleviates capacity constraints for healthcare providers. Halozyme reported a strong quarter, with royalty revenues up 65% and continued uptake of its drugs, along with expanding use-case indications from its pharmaceutical partners. Management raised full-year guidance for both revenues and earnings, which was well-received by investors. During the period, we trimmed our position as the share price appreciated, consistent with our disciplined valuation approach.

BSD Analysis:
Halozyme continues to reinforce its position as one of the most attractive royalty-driven growth stories in biopharma, anchored by the commercial momentum of its ENHANZE® subcutaneous delivery platform. The technology has become increasingly strategic for large-cap partners seeking to differentiate biologics and expand patient access, and its adoption curve appears far from saturated. Royalty growth remains the key value driver, and the latest results—highlighting 65% year-over-year expansion—underscore both strong end-market demand and a broadening portfolio of enabled molecules. The company’s model offers unusually high operating leverage: incremental ENHANZE-based launches require effectively no added cost from Halozyme, allowing royalty growth to translate cleanly into earnings power. The growing pipeline of partnered programs, particularly in oncology and immunology, provides multi-year visibility and diversification. Valuation is no longer distressed after the recent rerating, but relative to long-dated royalty compounding and emerging optionality from new partner indications, the stock still screen as attractive on a medium-term horizon. Risk remains concentrated in partner execution and competitive drug delivery technologies, though ENHANZE retains a meaningful head start and strong clinical validation. Overall, Halozyme represents a rare combination of durable royalty growth, high margins, and low capital intensity.

Pitch Summary:
Madrigal Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a non-alcoholic liver disease with a high unmet medical need. The stock performed well on evidence of a very strong commercial launch and execution of Rezdiffra, a new drug therapy that has put Madrigal on an annualized pace for more than $1 billion in new sales this year. With U.S. market penetration in the single digits, the therapy has the potential to grow into a multi-billion-dollar blockbuster over time. In addition, the company in-licensed an oral GLP-1 drug, and additional therapies in the pipeline also show promise of incremental growth. During the period, we trimmed our position as the share price appreciated, based on our valuation discipline.

BSD Analysis:
Madrigal has emerged as one of the most credible early leaders in the newly defined MASH therapeutic category, and early commercial data for Rezdiffra suggest demand is tracking well ahead of typical first-year launches in hepatology. The company is benefiting from its first-mover advantage, a clear clinical profile, and strong physician awareness in a disease area that has long lacked approved treatments. With U.S. penetration still in the very early stages, Rezdiffra’s current launch trajectory implies blockbuster potential even before broader primary-care adoption or international expansion. The economics of the franchise look attractive: high gross margins, expanding payer coverage, and growing specialist reach support a path to substantial operating leverage as scale builds. Madrigal’s decision to in-license an oral GLP-1 candidate adds an interesting strategic hedge, positioning the firm to participate in the metabolic-disease tailwinds reshaping the industry. Still, the company faces typical execution risks—competition from emerging entrants, reimbursement dynamics, and the operational challenge of scaling from a single-asset biotech into a commercial organization. Overall, Madrigal’s early commercial performance and differentiated positioning make it one of the more compelling pure-play MASH stories in the sector, albeit with valuation sensitivity given the rapid appreciation in shares.

Pitch Summary:
Align Technology, Inc. is a global leader in dental technology and the maker of Invisalign clear aligners. We were initially drawn to Align for its strong competitive position and innovative iTero digital scanning system, which enables clinicians to design more precise treatment plans and enhances the overall patient experience. The stock underperformed during the quarter as expectations for a demand rebound did not materialize. Patient conversion rates softened, most notably within the teen segment, where revenue growth slowed to 3%. In addition, market share gains reversed amid a weaker macroeconomic backdrop for discretionary dental procedures and a shift toward lower-cost wires and brackets. Given these dynamics, we trimmed our position during the period.

BSD Analysis:
Align Technology remains the global leader in clear aligners, supported by a deeply integrated digital workflow and the broad clinical adoption of its iTero scanner platform. The company’s competitive advantages—brand equity, scale, and a closed digital ecosystem—position it well for long-term share retention within the orthodontic market. However, 2025 demand trends have been weaker than anticipated, reflecting both cyclical pressure on discretionary dental spending and softer conversion rates, particularly among teens. Market share erosion to lower-cost traditional orthodontic methods suggests that price sensitivity is rising within key consumer cohorts. While Align retains substantial long-term optionality through international expansion and continued digitalization of orthodontics, near-term visibility is muted, and operating leverage works in reverse when volumes slow. The stock’s recent underperformance reflects this recalibration of recovery expectations. From a valuation perspective, Align still commands a premium multiple relative to traditional dental peers, leaving limited margin for error if revenue growth remains subdued. Overall, the long-term thesis around digital orthodontics remains intact, but the risk-reward skew appears more balanced until demand normalizes.

Pitch Summary:
Sprout Social, Inc. provides a leading platform that enables businesses to manage, monitor, and optimize their social media presence. The company’s platform is recognized for its intuitive design, ease of deployment, and direct integrations across major social networks—features that underpin its competitive advantage. Despite delivering results ahead of expectations, the stock underperformed during the period following another reduction in forward guidance. In a market environment increasingly rewarding a “beat and raise” pattern, this guidance reset overshadowed otherwise solid execution. We believe the resulting pullback was excessive, given Sprout’s durable double-digit growth trajectory, expanding margin profile, and compelling valuation. With a strong competitive position and growing relevance to modern enterprises, we used the share price weakness as an opportunity to modestly increase our position during the period.

BSD Analysis:
Sprout Social remains one of the stronger pure-play assets in social media management software, benefiting from a well-designed platform and deep native integrations that competitors have struggled to replicate. The company continues to post solid underlying execution, but the repeated resets to forward guidance have undermined investor confidence and overshadowed operational progress. In a market that increasingly punishes anything short of a “beat-and-raise” cadence, Sprout’s guidance posture has created a credibility discount relative to other high-growth SaaS names. Despite these stumbles, Sprout’s long-term fundamentals remain compelling: enterprises are consolidating their digital engagement tools, social channels continue to fragment and scale, and Sprout’s mix shift toward larger customers supports improving unit economics. With margins expanding and growth still firmly in the double digits, the recent derating appears to overstate the risk of a structural slowdown. If management can reestablish forecasting discipline, the stock has room for multiple expansion from its current depressed levels.

Pitch Summary:
Consensus Cloud Solutions returned to growth two quarters earlier than expected, reporting margins in the mid-50% range and securing a credit facility that resolved near-term debt concerns. The company trades at ~5x earnings with a 20% FCF yield, providing significant upside potential.

BSD Analysis:
Consensus Cloud Solutions appears to be emerging from its post-spinoff trough ahead of schedule, with the return to revenue growth and sustained mid-50% EBITDA margins signaling early stabilization of the core digital-communications platform. The renewal of a credit facility materially reduces liquidity overhang and provides flexibility for continued deleveraging, a key concern for investors over the past year. Despite modest top-line prospects, the company’s recurring-revenue base and structurally high margins support a free cash flow profile rarely seen at its size. Consensus Cloud Solutions appears to be emerging from its post-spinoff trough ahead of schedule, with the return to revenue growth and sustained mid-50% EBITDA margins signaling early stabilization of the core digital-communications platform. The renewal of a credit facility materially reduces liquidity overhang and provides flexibility for continued deleveraging, a key concern for investors over the past year. Despite modest top-line prospects, the company’s recurring-revenue base and structurally high margins support a free cash flow profile rarely seen at its size.

Pitch Summary:
Kirby shares weakened as barge utilization declined amid a softer regional refining mix, pressuring pricing. Despite near-term challenges, management’s long-term outlook remains positive, citing strong supply-demand dynamics and disciplined capacity additions. The fund added to its position during the quarter.

BSD Analysis:
Kirby’s recent share weakness reflects a normalization in barge utilization as a softer Gulf Coast refining mix weighed on spot pricing, a reversal from the unusually tight conditions of the past year. While near-term earnings may remain constrained, underlying industry fundamentals still appear constructive: the U.S. inland marine fleet is aging, newbuild activity remains muted, and regulatory hurdles continue to elevate barriers to entry. These dynamics should support a gradually tightening supply–demand balance once refinery throughput and product mix normalize. Kirby’s operating model—anchored in scale advantages, disciplined maintenance practices, and a resilient customer base—positions it to capture pricing leverage over the medium term. Management commentary continues to highlight firm multi-year demand from petrochemical and refined-product shippers, suggesting that current softness is cyclical rather than structural. At today’s valuation, the stock embeds conservative utilization assumptions, offering potential upside if industry conditions revert to historical averages.

Pitch Summary:
Sprout Social delivered results ahead of expectations but reduced forward guidance, triggering a selloff in a market focused on “beat and raise” dynamics. Despite this, its platform continues to demonstrate durable double-digit revenue growth, expanding margins, and strong customer adoption. The fund used the pullback to modestly increase its position.

BSD Analysis:
Sprout Social’s sharper-than-expected guidance reset overshadowed what were otherwise strong quarterly fundamentals, illustrating how dependent sentiment has become on flawless execution in the current software environment. While the lowered outlook raised questions about near-term sales efficiency and enterprise deal timing, the underlying demand for centralized social-media management tools remains robust, supported by channel proliferation and rising complexity across digital marketing stacks. Sprout continues to post durable double-digit revenue growth, with margin expansion signaling improving operating leverage as adoption scales. Despite the guidance revision, the company’s competitive positioning remains intact: its platform is recognized for ease of use, deep integrations, and strong retention among mid-market and enterprise customers. Valuation now embeds more conservative assumptions on sales productivity and customer acquisition, leaving room for upside if execution stabilizes. For long-term investors, the combination of consistent growth, expanding profitability, and a mission-critical product set suggests the recent pullback may present a more attractive entry point than headline reaction implies.

Pitch Summary:
Nuclear fuel and services provider Centrus Energy is benefiting from renewed interest in nuclear power in the US to support growing power demand tied to the AI boom. Centrus is a nuclear fuel broker with burgeoning enrichment capabilities, positioning it well as the US seeks to maintain domestic energy independence.

BSD Analysis:
Centrus is one of the very few U.S. players positioned to benefit directly from the geopolitical scramble to secure enriched uranium — a market that has quietly shifted from sleepy to strategic in record time. As the West races to unwind dependence on Russian enrichment, Centrus’ HALEU capability gives it a first-mover advantage in the fuel cycle for next-gen reactors and small modular reactors. The supply-demand imbalance is not a short-term story; it’s structural, and Centrus is one of the only companies with both technical expertise and regulatory approval to meet it. The company’s balance sheet has healed, the contract pipeline is strengthening, and the optionality from DOE partnerships is enormous. The stock still trades like a niche nuclear subcontractor even though it’s sitting on one of the most important chokepoints in the future energy landscape. If SMR adoption accelerates, Centrus is an asymmetric lever on the entire nuclear renaissance.

Pitch Summary:
Shares of mortgage servicing company Mr. Cooper Group rose as its acquisition by Rocket Companies closed as the quarter concluded. Investor sentiment has also been buoyed by the Fed’s recent rate cut, which should give a boost to housing and refinancing demand in the period ahead.

BSD Analysis:
Mr. Cooper Group is a high-quality mortgage servicer that benefits from the sticky, annuity-like nature of its servicing portfolio. The core investment thesis is that its acquisition by Rocket Companies will unlock massive scale and cost synergies, strengthening its position in the highly competitive mortgage market. Investor sentiment has been materially boosted by the Fed's interest rate cuts, which should ignite refinancing volumes and grow the origination business attached to its servicing platform. With a strong balance sheet and robust capital return potential, the company is well-positioned for sustained earnings growth. The combined platform's expanded scale and cross-sell potential should drive ROE improvement and multiple expansion from currently modest levels.

Pitch Summary:
Huntington Ingalls is seeing progress from its efforts to improve employee attrition. Management expects demand to remain strong as the DOD prepares for potential Pacific conflicts, ensuring multi-year backlog visibility. Labor improvement should aid margin expansion.

BSD Analysis:
Huntington Ingalls is the unrivaled prime contractor for the U.S. Navy, benefiting from structural, multi-decade defense spending that underpins a robust backlog. Its position as the sole builder of nuclear-powered aircraft carriers and major subs creates a moat virtually impossible to breach, ensuring multi-year revenue visibility. Management has successfully executed a turnaround focused on labor stabilization and efficiency, which is driving an expected margin expansion trajectory. With over $45 billion in backlog and a predictable free cash flow yield, the company is fundamentally undervalued relative to its peers. Continued improvement in labor productivity and sustained DoD funding will act as key catalysts to close the valuation gap.

Pitch Summary:
Industrial distributor WESCO’s data center business is growing rapidly, in turn driving revenue growth. Signs of strong organic growth and improvement in its high-margin utility business further contributed. Management sees secular tailwinds from infrastructure, automation, and electrification.

BSD Analysis:
WESCO International is a dominant industrial distributor aggressively leveraging its scale to capture secular tailwinds in electrification and AI data centers. The core thesis is a classic integration story, with the company extracting significant synergy savings from its recent merger while benefiting from accelerating demand in its high-margin utility and data center businesses. Its scale and network advantages are indispensable to the buildout of critical infrastructure and industrial automation. With operating margin recovery underway and a disciplined approach to deleveraging, the company is poised for significant EPS growth. Trading at an attractive EV/EBITDA multiple relative to industrial peers, WESCO offers a compelling blend of cyclical recovery and structural growth.

Pitch Summary:
Strong demand for networking systems company Ciena’s hyperscaler offerings has helped drive strong earnings growth. Hyperscaler demand is being fueled by AI-related projects, which management believes should translate to durable demand ahead.

BSD Analysis:
Ciena remains the backbone of high-capacity optical networking, with demand accelerating as cloud providers and telecom operators upgrade networks for AI workloads, 800G deployments, and growing east–west traffic. The company’s WaveLogic coherent modem leadership is translating into robust design wins and expanding customer share across hyperscalers. Supply-chain normalization is lifting margins, and software and services continue to enhance recurring revenue and profitability. While telecom budgets remain uneven, hyperscaler demand more than offsets the softness and gives Ciena a strong multi-year growth trajectory. Despite its strategic positioning, the stock trades below its intrinsic value due to cyclical hesitation in network spending. With AI-era bandwidth requirements surging, Ciena remains one of the most durable beneficiaries of long-haul and metro optical infrastructure modernization.

Pitch Summary:
Fortrea helps its biotech and pharmaceutical customers to run clinical trials with the goal of receiving marketing authorization in the U.S. and other countries. Fortrea helps design the trials, recruit investigators and participants, prepare data for regulatory review, and other tasks needed to win the authorization to market new treatments. The company spun out of Labcorp in June 2023, and is attempting to turn around the business. Fortrea currently trades at an attractive upside-to-downside ratio.

BSD Analysis:
Fortrea is still working through the messy aftermath of its spin, but the market is beginning to acknowledge the operational cleanup and commercial stabilization underway. The company inherited structural inefficiencies and legacy contracts that weighed on margins, yet early progress on cost actions, backlog quality, and client retention suggests the trough is behind it. While the CRO landscape is competitive, Fortrea’s scale, therapeutic breadth, and global delivery network provide a credible platform once integration issues are fully resolved. Cash flow visibility remains limited near term, but operational improvements should unlock meaningful margin recovery as the business normalizes. Valuation reflects deep skepticism, offering asymmetric upside if Fortrea can execute even a modest turnaround. This remains a classic small-cap self-help story with a wide gap between sentiment and improving fundamentals.

Pitch Summary:
With Thinkific, we bought shares in a Canadian company that helps its customers create and get paid for online courses. It is managed by one of its founders, and it is shedding customers as it pursues a new strategy targeting larger, higher lifetime-value customers. Despite the lower customer count, management has continued to find ways to grow revenue and improve cash flow. We paid C$1.87 per share, which I thought was a fine price for a well-managed business that should grow over time.

BSD Analysis:
Thinkific got caught in the post-pandemic hangover as creator-economy hype collapsed, but the underlying business is far stronger than the market narrative. The platform remains a best-in-class toolset for course creators, coaches, and small businesses that need a polished, scalable learning infrastructure. While growth slowed, Thinkific used the downturn wisely: tightened operating costs, revamped product features, and improved monetization through payments, communities, and bundles. Gross margins are healthy, the path to profitability is getting clearer, and the company is building a more predictable revenue base as creators professionalize their operations. The stock still trades like a busted COVID beneficiary despite having real competitive differentiation and a long-term tailwind as more businesses shift training and education online. Thinkific doesn’t need the creator boom to return — steady execution and disciplined cost control are enough to drive meaningful upside from here.

Pitch Summary:
GetBusy was already our largest position, but we bought a bit more (paying £0.66/share) after management forecast “material acceleration” in the SmartVault business. Then each of the CFO, CEO and a director added weight to those words by personally buying stock.

BSD Analysis:
GetBusy is the definition of a microcap that’s far more interesting than its market cap suggests. The company operates workflow, document management, and productivity tools designed for accountants and SMBs — niche markets, yes, but with ridiculously sticky customer bases and high retention. Revenue is recurring, churn is low, and GetBusy’s product improvements are pushing it toward better monetization without cranking up costs. The balance sheet is lean, burn is controlled, and the company has been edging toward breakeven with surprising consistency. GetBusy doesn’t need explosive growth to win — it just needs to keep compounding within its defensible niches while maintaining discipline. The market ignores it because it’s small, but operational execution keeps getting better. If management continues smoothing the revenue base and sharpening margins, this is one of those microcaps that quietly re-rates long before the broader market notices.

Pitch Summary:
Later in the quarter we sold shares of Credit Acceptance, reducing it to a bit more than 1% of the fund. We used the bulk of the proceeds to buy Kontoor, a stock that we have owned before. Kontoor spun out of VF Corp in 2019, comprising the jeans businesses Wrangler, and Lee. Since the spinoff, Kontoor has been a well-managed cash cow that has paid dividends and repurchased its stock. I think the Kontoor story changed earlier this year when the company bought Helly Hansen, an Outdoor and Workwear brand. The acquisition closed in July and appears to be going well. Before this acquisition, Kontoor was a well-managed cash cow that did not grow, as exemplified by their annual revenues still lagging behind their 2007 level. With the Helly Hansen acquisition, Kontoor appears to be dusting off the old VF Corp playbook: borrow to buy a good brand, manage it well, pay down debt, and repeat. Adding growth makes a well-managed cash cow more valuable, and that is what I believe is happening at Kontoor. We paid $72.54/share for our position.

BSD Analysis:
Kontoor is the denim cash machine investors keep sleeping on because the brands — Wrangler and Lee — aren’t dripping with hype. But the reality is simple: these labels have insane global recognition, stable demand, and supply-chain discipline that would embarrass larger apparel companies. Gross margins are expanding as Kontoor leans into DTC, tightens inventory, and pushes premiumization without alienating the value-conscious core. International markets — especially China — remain a massive under-monetized opportunity, and management is finally treating global growth as a priority instead of an afterthought. Free cash flow is consistently strong, the dividend is rock solid, and capital allocation is refreshingly rational. At today’s valuation, the stock trades like a dying legacy brand even though Kontoor has one of the cleanest balance sheets and most predictable earnings profiles in apparel. This is a boring-but-beautiful compounder hiding in plain sight.

Pitch Summary:
While Enhabit has been doing fairly well with its turnaround, I did not like the increasing headwinds facing the business and decided that we would be better off investing our money elsewhere. In early July, the Centers for Medicare and Medicaid Services (CMS) proposed cutting Medicare home health reimbursement rates even more aggressively than they have in the past few years. Medicare is Enhabit’s best-paying customer, and this cut—deeper than those of the past few years—was unexpected. With the prospect of not only continuing rate cuts but even deeper rate cuts, I reduced my valuation for the company. Enhabit has navigated the home health industry headwinds well so far, and its Hospice business is doing very well, but the headwinds are worse than I thought. As the U.S. population ages, demand for home health services will grow, but getting CMS and insurers to pay the rates that will allow home health companies to profitably expand supply now appears more challenging than I had expected.

BSD Analysis:
Enhabit is a deep-value home health and hospice spin-off struggling under a severe regulatory headwind that has structurally eroded its cash flow profile. The fund exited the position because the Centers for Medicare and Medicaid Services (CMS) aggressively cut home health reimbursement rates, which the manager views as a policy risk that is now worse than expected. While long-term demographics are favorable for home health, the margin compression from deep, unexpected rate cuts in a fixed-cost business model significantly caps future upside. The stock, trading around 8x forward EV/EBITDA and facing stagnant earnings visibility, warranted a pragmatic exit to redeploy capital into higher-growth, less policy-sensitive names. Despite management's ability to navigate past headwinds, the policy risk and limited pricing leverage make the turnaround path too challenging.

Pitch Summary:
Johnson & Johnson is a major healthcare company focused on innovative pharmaceuticals and medical devices. The company faces a critical transition as sales from its blockbuster drug Stelara begin to decline due to patent expiration. However, J&J is successfully executing on its strategy to offset these losses with a robust pipeline of new drugs, particularly in oncology and immunology. The stock responded positively in the quarter as the company demonstrated significant progress on multiple fronts. It secured a landmark FDA approval for Inlexzo, a new bladder cancer treatment with substantial sales potential, and its lung cancer drug Rybrevant moved closer to broader adoption after receiving positive trial data for a more convenient injection format. Strong sales momentum across other key drugs more than compensated for Stelara's decline, while favorable legal developments eased investor concerns about the company's ongoing talc litigation.

BSD Analysis:
Johnson & Johnson is executing a high-stakes pipeline defense to neuter the imminent Stelara patent cliff, ensuring its prized dividend crown remains secure. The company is systematically offsetting the inevitable loss of exclusivity with a robust, high-value pipeline in key franchises like oncology and immunology. Recent wins, including the landmark FDA approval for Inflexzo (bladder cancer) and positive data for its lung cancer drug, Rybrevant, provide tangible proof the strategy is working. Beyond pharmaceuticals, the diversified, durable medical devices business provides essential, non-cyclical cash flow resilience. Favorable legal developments around the long-standing talc litigation are now easing investor anxiety, removing a major overhang and clearing the path for the company to focus on its structural growth drivers.

Pitch Summary:
D.R. Horton, Inc. is the largest homebuilder in the United States by volume, with a strategic focus on the entry-level and first-time buyer segments. Our investment thesis centers on the company's ability to leverage its unmatched scale and production-oriented model to deliver affordable homes, a compelling value proposition in a market challenged by affordability. Its extensive presence across numerous high-growth Sunbelt markets solidifies its leadership position. The company’s operational efficiency drives strong cash flow generation, enabling significant capital returns to shareholders through buybacks while maintaining a 'land-light' strategy that reduces balance sheet risk. The stock outperformed during the quarter after the company reported surprising results across several metrics, including stronger-than-expected home closings and new orders (flat versus an expected decline), resilient gross margins that beat prior guidance, and a 2% year-over-year decline in construction costs. Management also raised share repurchase guidance, signaling confidence in future cash flows.

BSD Analysis:
D.R. Horton continues to prove why it’s the dominant force in U.S. homebuilding, leveraging scale, land discipline, and a broad product mix to capture outsized share in a chronically undersupplied market. The company’s focus on affordable and entry-level homes aligns perfectly with demographic and migration trends, driving exceptional absorption rates even in a high-rate environment. Margins have held up better than peers due to tight cost control, smart incentives, and an efficient build-to-order model. Cash flow remains robust, the balance sheet is pristine, and capital returns continue to enhance per-share value. Despite strong fundamentals, the stock still trades at a conservative multiple due to macro housing fears that have yet to materialize in DHI’s results. With structural supply shortages and demand resilience intact, D.R. Horton remains one of the cleanest long-term compounders in housing.

Pitch Summary:
Intercontinental Exchange, Inc. operates a global network of exchanges, clearing houses, and data services spanning major asset classes, including energy, equities, fixed income, and U.S. residential mortgages. We like the company for its resilient business model. It combines transaction-based revenues that benefit from market volatility with a growing base of recurring data and technology revenues, each generating strong, consistent cash flow for debt reduction and shareholder returns. The stock underperformed during the quarter, however, we maintain confidence in the company’s long-term potential.

BSD Analysis:
ICE continues to distinguish itself as one of the most durable data-and-exchange franchises, with high-recurring revenue, strong pricing power, and an expanding footprint across market infrastructure. The integration of Black Knight broadens ICE’s reach into mortgage tech, creating a more diversified growth engine that should benefit from long-term digitization of the mortgage ecosystem. Core exchange and clearing operations remain resilient, supported by deep liquidity pools and mission-critical data services. The company’s discipline in cost management and high cash conversion support consistent buybacks and dividend growth. While the stock often trades like a sleepy exchange operator, the combination of structural data demand and secular fintech penetration provides a long runway of double-digit EPS growth. ICE remains one of the clearest quality compounders in financial infrastructure.